Immunotherapy for hepatocellular carcinoma
Y Zongyi, L Xiaowu - Cancer letters, 2020 - Elsevier
abstract Despite significant research efforts, only a few treatment approaches have been
developed for hepatocellular carcinoma (HCC). In recent years, immune checkpoint …
developed for hepatocellular carcinoma (HCC). In recent years, immune checkpoint …
[HTML][HTML] Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies
H Cheng, G Sun, H Chen, Y Li, Z Han, Y Li… - American journal of …, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase …
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase …
Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma
PF Zhang, C Gao, XY Huang, JC Lu, XJ Guo, GM Shi… - Molecular cancer, 2020 - Springer
Objective Natural killer (NK) cells play a critical role in the innate antitumor immune
response. Recently, NK cell dysfunction has been verified in various malignant tumors …
response. Recently, NK cell dysfunction has been verified in various malignant tumors …
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Chimeric antigen receptor (CAR) therapy is a promising immunotherapeutic strategy for
treating multiple refractory blood cancers, but further advances are required for solid tumor …
treating multiple refractory blood cancers, but further advances are required for solid tumor …
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma
J Cai, Z Chen, Y Zhang, J Wang, Z Zhang, J Wu… - Molecular Therapy …, 2022 - cell.com
Circular RNAs are a class of highly conserved RNAs with stable covalently closed circular
structures. Metabolic reprogramming of cancer cells reshapes the tumor microenvironment …
structures. Metabolic reprogramming of cancer cells reshapes the tumor microenvironment …
[HTML][HTML] Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell …
H Deng, A Kan, N Lyu, L Mu, Y Han, L Liu, Y Zhang… - Liver cancer, 2020 - karger.com
Abstract Background and Aims: Combining anti-angiogenic therapy with immune checkpoint
blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for …
blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for …
Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by …
J Sheng, J Zhang, L Wang, V Tano, J Tang, X Wang… - Gut, 2022 - gut.bmj.com
Objective Hepatocellular carcinoma (HCC) tumour microenvironment (TME) is highly
complex with diverse cellular components organising into various functional units, cellular …
complex with diverse cellular components organising into various functional units, cellular …
Integrated analysis of immunity-and ferroptosis-related biomarker signatures to improve the prognosis prediction of hepatocellular carcinoma
X Du, Y Zhang - Frontiers in genetics, 2020 - frontiersin.org
Background Hepatocellular carcinoma (HCC) is a common malignant tumor with high
mortality and poor prognoses around the world. Ferroptosis is a new form of cell death, and …
mortality and poor prognoses around the world. Ferroptosis is a new form of cell death, and …
Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy
RY Zhang, D Wei, ZK Liu, YL Yong, W Wei… - Frontiers in Cell and …, 2019 - frontiersin.org
Chimeric antigen receptor T cell (CAR-T) therapy to hematological malignancies has
demonstrated tremendous clinical outcomes. However, the therapeutic efficacy of CAR-T …
demonstrated tremendous clinical outcomes. However, the therapeutic efficacy of CAR-T …
Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice
J Zhang, XT Lin, HQ Yu, L Fang, D Wu… - … & Molecular Medicine, 2023 - nature.com
Metastatic hepatocellular carcinoma (HCC) is the most lethal malignancy and lacks effective
treatment. FBXL6 is overexpressed in human hepatocellular carcinoma (HCC), but whether …
treatment. FBXL6 is overexpressed in human hepatocellular carcinoma (HCC), but whether …